Search
Liraglutide
go.drugbank.com/drugs/DB06655ApprovedInvestigationalVictoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. … [A6932] Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor.
Salmeterol
go.drugbank.com/drugs/DB00938ApprovedInvestigational[A183737] Salmeterol was granted FDA approval on 4 February 1994.[L11542] … [L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol].
Mixtures: SERETIDE FORTE50/500UG D, SERETIDE FORTE50/500UG DBrigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigational[A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026] … Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR).
Categories: Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexGimeracil
go.drugbank.com/drugs/DB09257ApprovedInvestigationalBy mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, 5-FU is able to insert itself into strands of DNA and RNA, thereby halting the replication process necessary … The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells.
Dendritic cells vaccine
go.drugbank.com/drugs/DB15803InvestigationalThe recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and effectiveness against SARS-CoV-2-induced pneumonia. … With a better safety profile than inactivated and live-attenuated virus and virus-vector vaccines, the recombinant chimeric DC vaccine reduces the risk of virulence recovery, pre-existing anti-vector immunity
Synonyms: Recombinant chimeric COVID-19 DC vaccine, Recombinant chimeric COVID-19 epitope DC vaccine;Licofelone
go.drugbank.com/drugs/DB04725ExperimentalIt is currently under evaluation as a treatment for osteoarthritis (OA), the most common form of arthritis. … Although phase III trials have been successfully completed in OA patients no dates for regulatory submission have yet been given.
Allogeneic processed thymus tissue
go.drugbank.com/drugs/DB16736Approved[L38929] Congenital athymia is a rare condition that leads to the absence of a thymus at birth and a high premature mortality rate, with patients typically dying by age two or three. … [A239814] On October 8, 2021, FDA approved allogeneic processed thymus tissue-agdc, under the market name RETHYMIC, as a one-time regenerative tissue-based therapy for immune reconstitution in pediatric
Fecal microbiota
go.drugbank.com/drugs/DB17743ApprovedInvestigationalRecurrent CDI has a high risk of mortality and a high failure rate. … [A259172] REBYOTA, a live fecal microbiota suspension for rectal use, was approved by the FDA in November 2022.
CHF5633
go.drugbank.com/drugs/DB18696InvestigationalCHF5633 is a fully synthetic pulmonary surfactant preparation comprising DPPC (dipalmitoylphosphatidylcholine), POPG Na (palmitoyl‐oleoyl‐phosphatidylglycerol sodium), a synthetic SP-C analogue, and a
Synonyms: Synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogueVeliflapon
go.drugbank.com/drugs/DB16346InvestigationalVeliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).